Measuring compliance

Otuska's Abilify MyCite, the first FDA-approved pill that notifies physicians when the pill is consumed, is being rolled out to Medicaid patients in Florida. The pill costs approximately $1650/month. Bioethicists weighed in on the ethics of measuring compliance, and ultimately FDA approved the pill. What do you think? Is the public health threat of schizophrenia a greater concern than patient autonomy? Does the fact that it is going to Medicaid patients only in this first rollout modify your reasoning?


Add new comment